# Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

> **NCT06674135** · PHASE4 · COMPLETED · sponsor: **Life for a Child Program, Diabetes Australia** · enrollment: 202 (actual)

## Conditions studied

- Type I Diabetes

## Interventions

- **DRUG:** biosimilar insulin glargine

## Key facts

- **NCT ID:** NCT06674135
- **Lead sponsor:** Life for a Child Program, Diabetes Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2024-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674135, "Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06674135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*